Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting
Accuray (NASDAQ: ARAY) presented new clinical data for its CyberKnife® System at the 2025 Radiosurgery Society Scientific Meeting, demonstrating its effectiveness in treating central nervous system tumors. Key findings include:
- A 25-year study showed 89.3% local control rate and 97.1% overall survival for vestibular schwannoma treatments
- Donut-shaped circumferential SBRT proved safe and effective for spinal metastases
- In elderly patients with trigeminal neuralgia, 90% experienced pain improvement or elimination
- For occipital condyle metastasis, the treatment achieved 93.8% local tumor control over three years, with 87.5% of patients experiencing pain relief
The CyberKnife System utilizes image guidance during treatment, leveraging up to 1,000 different beam angles and Synchrony® adaptive delivery technology to adjust for tumor or patient motion in real-time.
Accuray (NASDAQ: ARAY) ha presentato nuovi dati clinici per il suo sistema CyberKnife® durante il Meeting Scientifico della Radiosurgery Society del 2025, dimostrando la sua efficacia nel trattamento dei tumori del sistema nervoso centrale. I principali risultati includono:
- Uno studio di 25 anni ha mostrato un tasso di controllo locale dell'89,3% e un tasso di sopravvivenza complessiva del 97,1% per i trattamenti del neuroma vestibolare.
- La SBRT circonferenziale a forma di ciambella si è dimostrata sicura ed efficace per le metastasi spinali.
- Nei pazienti anziani con nevralgia del trigemino, il 90% ha riportato un miglioramento o l'eliminazione del dolore.
- Per la metastasi dell'occcipite, il trattamento ha raggiunto un controllo locale del tumore del 93,8% in tre anni, con l'87,5% dei pazienti che ha sperimentato un sollievo dal dolore.
Il sistema CyberKnife utilizza la guida per immagini durante il trattamento, sfruttando fino a 1.000 angoli di fascio diversi e la tecnologia di somministrazione adattiva Synchrony® per adattarsi in tempo reale al movimento del tumore o del paziente.
Accuray (NASDAQ: ARAY) presentó nuevos datos clínicos para su sistema CyberKnife® en la Reunión Científica de la Sociedad de Radioscirugía de 2025, demostrando su eficacia en el tratamiento de tumores del sistema nervioso central. Los hallazgos clave incluyen:
- Un estudio de 25 años mostró una tasa de control local del 89,3% y una tasa de supervivencia general del 97,1% para los tratamientos de schwannoma vestibular.
- La SBRT circunferencial en forma de donut demostró ser segura y eficaz para las metástasis espinales.
- En pacientes ancianos con neuralgia del trigémino, el 90% experimentó una mejora o eliminación del dolor.
- Para la metástasis del cóndilo occipital, el tratamiento logró un control local del tumor del 93,8% durante tres años, con el 87,5% de los pacientes experimentando alivio del dolor.
El sistema CyberKnife utiliza guía de imágenes durante el tratamiento, aprovechando hasta 1,000 ángulos de haz diferentes y la tecnología de entrega adaptativa Synchrony® para ajustarse en tiempo real al movimiento del tumor o del paciente.
Accuray (NASDAQ: ARAY)는 2025년 방사선 수술 학회의 사이버나이프® 시스템에 대한 새로운 임상 데이터를 발표하여 중추 신경계 종양 치료의 효과를 입증했습니다. 주요 발견 사항은 다음과 같습니다:
- 25년 연구에서 전정 신경종 치료에 대해 89.3%의 국소 제어율과 97.1%의 전체 생존율을 보여주었습니다.
- 도넛 모양의 원주 SBRT는 척추 전이 치료에 안전하고 효과적임을 입증했습니다.
- 삼차신경통이 있는 노인 환자의 90%가 통증 개선 또는 완화를 경험했습니다.
- 후두 결절 전이에 대해 치료는 3년 동안 93.8%의 국소 종양 제어를 달성했으며, 87.5%의 환자가 통증 완화를 경험했습니다.
사이버나이프 시스템은 치료 중 이미지 가이드를 사용하여 최대 1,000개의 다양한 빔 각도와 실시간으로 종양이나 환자 움직임에 맞춰 조정하는 Synchrony® 적응형 전달 기술을 활용합니다.
Accuray (NASDAQ: ARAY) a présenté de nouvelles données cliniques pour son système CyberKnife® lors de la Réunion Scientifique de la Société de Radiosurgie de 2025, démontrant son efficacité dans le traitement des tumeurs du système nerveux central. Les principales conclusions incluent:
- Une étude de 25 ans a montré un taux de contrôle local de 89,3% et un taux de survie global de 97,1% pour les traitements de schwannome vestibulaire.
- La SBRT circonférentielle en forme de beignet s'est révélée sûre et efficace pour les métastases spinales.
- Chez les patients âgés souffrant de névralgie du trijumeau, 90% ont connu une amélioration ou une élimination de la douleur.
- Pour la métastase du condyle occipital, le traitement a atteint un contrôle local de la tumeur de 93,8% sur trois ans, avec 87,5% des patients ressentant un soulagement de la douleur.
Le système CyberKnife utilise l'imagerie guidée pendant le traitement, tirant parti de jusqu'à 1 000 angles de faisceau différents et de la technologie de livraison adaptative Synchrony® pour s'ajuster en temps réel aux mouvements du tumeur ou du patient.
Accuray (NASDAQ: ARAY) stellte auf dem wissenschaftlichen Treffen der Radiosurgery Society 2025 neue klinische Daten zu seinem CyberKnife®-System vor, die dessen Wirksamkeit bei der Behandlung von Tumoren des zentralen Nervensystems demonstrieren. Wichtige Erkenntnisse sind:
- Eine 25-jährige Studie zeigte eine lokale Kontrollrate von 89,3% und eine Gesamtüberlebensrate von 97,1% bei der Behandlung von vestibulären Schwannomen.
- Die donutsförmige zirkumferentielle SBRT erwies sich als sicher und effektiv bei spinalen Metastasen.
- Bei älteren Patienten mit trigeminaler Neuralgie erlebten 90% eine Schmerzlinderung oder -eliminierung.
- Bei Metastasen des Occipitalen Kondylus erreichte die Behandlung innerhalb von drei Jahren eine lokale Tumorkontrolle von 93,8%, wobei 87,5% der Patienten Schmerzlinderung erfuhren.
Das CyberKnife-System nutzt während der Behandlung bildgestützte Führung und nutzt bis zu 1.000 verschiedene Strahlwinkel sowie die adaptive Liefertchnologie Synchrony®, um sich in Echtzeit an die Bewegung des Tumors oder des Patienten anzupassen.
- Strong long-term efficacy data with 89.3% local control rate over 25 years
- High success rates across multiple conditions: 90% pain improvement in trigeminal neuralgia
- 93.8% local tumor control in occipital condyle metastasis over 3 years
- Demonstrated safety and effectiveness in treating complex spinal metastases
- None.
Insights
The clinical data presented at the Radiosurgery Society meeting provides compelling validation for Accuray's CyberKnife platform in treating central nervous system tumors. The 25-year retrospective study showing
What's particularly significant is the system's demonstrated versatility across challenging treatment scenarios. The donut-shaped circumferential SBRT technique for spinal metastases addresses a critical clinical challenge – delivering effective radiation doses while avoiding spinal cord damage. For elderly trigeminal neuralgia patients, the
The
These outcomes collectively strengthen Accuray's clinical positioning in the competitive radiotherapy market by demonstrating the platform's precision delivery capabilities across multiple neurological applications. The data suggests CyberKnife offers meaningful solutions for conditions where treatment options are , potentially expanding its addressable market beyond traditional radiation therapy applications.
These new studies highlight CyberKnife's technical advantages in managing complex central nervous system tumors. The system's ability to leverage up to 1,000 different beam angles combined with real-time adaptive delivery through Synchrony technology enables the precision required for these challenging anatomical locations.
The long-term vestibular schwannoma data is particularly noteworthy. VS tumors present unique challenges given their proximity to critical structures like the brainstem and cranial nerves, where surgical approaches carry significant risk. Achieving
For spinal metastases, the donut-shaped circumferential technique represents a clever solution to the fundamental challenge in spine radiosurgery – delivering ablative doses to the tumor while sparing the adjacent spinal cord. This approach maximizes the therapeutic ratio, providing effective tumor control without myelopathy.
The trigeminal neuralgia outcomes in elderly patients (80-100 years) address an important clinical gap, as this population often cannot tolerate microvascular decompression surgery or may have medication contraindications. Similarly, occipital condyle metastases represent a challenging location where surgical access is difficult and radiation targeting is complex.
These applications demonstrate how advanced delivery techniques can expand treatment indications, providing options for patients previously considered untreatable or at high risk for conventional approaches. The data reinforces CyberKnife's value proposition as a versatile platform capable of addressing complex clinical scenarios with non-invasive precision.
Data Also Highlights Continued Clinical Advances Using the CyberKnife System That are Making
High Quality Care an Option for People Who Previously Had Limited Choices
SRS and SBRT are non-surgical procedures that deliver precisely targeted doses of radiotherapy, typically in one to five treatment sessions, with the goal of ablating (destroying) the tumor or lesion. To achieve the accuracy and precision required, the CyberKnife System uses image guidance during treatment, and leverages potentially 1,000 different beam angles targeting the tumor as well as Synchrony® adaptive delivery, which adjusts the aim of the beam in real time to correct for tumor or patient motion.
"The studies presented at this year's Radiosurgery Society meeting underscore both the long-term efficacy and expanding applications of the CyberKnife System. Whether treating benign tumors like vestibular schwannoma or managing complex conditions such as spinal metastases and trigeminal neuralgia, the common thread is the need for precise, highly targeted radiation delivery — a hallmark of the CyberKnife System. These new data not only reinforce its value in central nervous system treatments but also add to the growing body of evidence supporting its role in improving both the quality and longevity of patients' lives," said Seth Blacksburg, M.D., MBA, Chief Medical Officer at Accuray.
RSS CyberKnife System Study Highlights: Advancing and Expanding Patient Care
25-Year Data Supports the Use of the CyberKnife System to Treat Vestibular Schwannoma (VS)
- 25-year data were reported for patients in a single institution study retrospectively evaluating SRS for the treatment of VS (also known as acoustic neuroma) using the CyberKnife System. A non-cancerous, usually slow-growing brain tumor, VS can cause hearing loss, ringing in the ear, and dizziness or loss of balance. The study demonstrated treatment with the system provides sustained local tumor control and long-term efficacy. At 25 years, the local control rate was 89.3 percent and overall survival was 97.1 percent 2.
Clinical Innovation Facilitates Treatment of Challenging Condition Using the CyberKnife System
- A study evaluated the safety and efficacy of donut-shaped circumferential stereotactic body radiation therapy (SBRT) delivered using the CyberKnife System for the treatment of spinal metastases. This treatment technique is designed to target the spinal column while avoiding the spinal cord. High doses of radiation delivered to the spinal cord can result in serious complications, such as radiation myelopathy, causing injury or paralysis. Study investigators concluded, "Donut-shaped circumferential CyberKnife SBRT is a safe and effective treatment for spinal metastases, achieving high local tumor control with minimal radiation-induced complications, including myelopathy 3."
CyberKnife System Expands Treatment Options for Patients with Painful Neurological Conditions
Trigeminal neuralgia and occipital condyle metastasis are rare conditions often causing excruciating pain that may impact all aspects of patients' daily life.
- A study of elderly patients (aged 80 to 100 years) with trigeminal neuralgia found that radiosurgery delivered using the CyberKnife System provides excellent outcomes. Pain improved or disappeared in 90 percent of those evaluated and only three percent developed paresthesia – a sensation of tingling, "pins and needles" or numbness – considered bothersome. Data indicate radiosurgery provides an option for a patient population that may have limited choices because health issues preclude surgery or they are unresponsive to medication4.
- An evaluation of SRS for occipital condyle metastasis (OCM) using the CyberKnife System found the treatment offers significant pain relief, excellent local control rates and improvement in neurological symptoms. A 93.8 percent local tumor control rate was achieved over three years. Of patients who reported symptoms, 87.5 percent experienced pain relief. Study authors concluded, "This non-invasive therapy provides a valuable alternative to surgery, potentially enhancing the quality of life for patients with limited treatment options due to this challenging condition5."
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 5, 2025, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
1 Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, Fuchs HE, Waite KA, Jemal A, Siegel RL, Barnholtz-Sloan JS. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021 Sep;71(5):381-406. doi: 10.3322/caac.21693. Epub 2021 Aug 24. PMID: 34427324.
2 "Long-Term Outcomes of Vestibular Schwannoma Treated with Stereotactic Radiosurgery: A Retrospective Study from a Single Institution." 2025 RSS Scientific Meeting.
3 "Efficacy and Safety of Donut-Shaped Circumferential Spine CyberKnife Stereotactic Body Radiotherapy for Metastatic Spine Disease." 2025 RSS Scientific Meeting.
4 "Frameless Radiosurgery Is a Safe and Effective Treatment for Medically-Refractory Trigeminal Neuralgia in Elderly Patients." 2025 RSS Scientific Meeting.
5 "Efficacy and Safety of CyberKnife Stereotactic Radiosurgery for Occipital Condyle Metastasis." 2025 RSS Scientific Meeting.
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-cyberknife-platform-featured-in-new-studies-showcasing-its-benefits-in-central-nervous-system-tumors-presented-at-radiosurgery-society-scientific-meeting-302419454.html
SOURCE Accuray Incorporated
FAQ
What are the 25-year success rates for CyberKnife treatment of vestibular schwannoma according to ARAY's latest data?
How effective is ARAY's CyberKnife System for treating trigeminal neuralgia in elderly patients?
What are the success rates of CyberKnife treatment for occipital condyle metastasis presented at the 2025 RSS meeting?
How does ARAY's CyberKnife System deliver targeted radiation therapy?
